Progress against Cancer in Kids | Quit Smoking | Never Smokers, Cancer Information Highlights, 09/29/2021

Having trouble viewing this email? View it as a Web page.

Cancer Information Highlights From the National Cancer Institute Updating you about cancer causes, prevention, screening, treatment, coping, and more   New from NCI A Promising Future for Progress against Childhood Cancer   NCI Director Dr. Ned Sharpless discusses progress against childhood cancers, such as using CAR T-cell therapy and collecting more complete data on young people with cancer, and the need to better address cancer disparities in kids. Quitting Smoking Improves Survival in People with Lung Cancer   People who quit smoking after learning they have early-stage lung cancer may live longer than those who do not quit smoking. A new study, which included more than 500 people, also found that quitting smoking delayed cancer from returning or getting worse. Study Sheds Light on Origins of Lung Cancer in Never Smokers NCI scientists and their collaborators have found that most lung cancers in never smokers arise when changes caused by natural processes in the body build up. They also found three subtypes of lung cancer in these people. Extra or Missing Chromosomes May Help Cancer Cells Survive Treatment Aneuploidy—when cells have too many or too few chromosomes—is common in cancer cells. Two new studies suggest that aneuploidy helps cancer cells survive treatments like chemotherapy and targeted therapies. Clinical Trials: Bringing Cancer Research to All Possible Participants   Ending cancer as we know it means reimagining clinical trials so that people can take part in research wherever they are. This section of the NCI Annual Plan & Budget Proposal for Fiscal Year 2023 describes ways that NCI is working to expand access to these important research studies. Belzutifan Approved for Tumors Linked to von Hippel-Lindau Disease (VHL) The Food and Drug Administration (FDA) has approved belzutifan (Welireg) to treat adults with VHL who have tumors of the kidney, brain, nervous system, or pancreas. The drug may help these people avoid or delay surgery by shrinking their tumors. Profiling the People behind Cancer Screening and Early Detection Research   Read about Dr. Worta McCaskill-Stevens, a codesigner and participant in a breast cancer screening trial, and Dr. David Sidransky, whose research uses biomarkers to improve the early detection of cancer. PDQ Updates Acute Myeloid Leukemia Treatment We've updated our summary on the treatment of acute myeloid leukemia in adults with revisions to all sections. FDA Approvals Cabozantinib-S-Malate We've updated our drug summary on cabozantinib-s-malate (Cabometyx) with a new FDA approval. The drug was recently approved for use in adults and children aged 12 and older with differentiated thyroid cancer that has spread and has gotten worse after targeted therapy and cannot be treated with radioactive iodine.   Also of Interest Late Effects of Treatment for Childhood Cancer Cancer treatment may cause health problems for childhood cancer survivors months or years after treatment has ended. Learn about the late effects of treatment for childhood cancer and how follow-up care and good health habits can improve quality of life. Coronavirus: What People with Cancer Should Know Learn how to protect yourself from COVID-19 and find information on extra vaccine shots for people with weakened immune systems. Contact Us for Help Information specialists at NCI's Cancer Information Service (CIS), NCI's contact center, are available to help answer your cancer-related questions in English and Spanish. Reach us by phone, chat, or email.

Stay Connected with the National Cancer Institute
Chat with us: LiveHelp       Call us: 1-800-4-CANCER (1-800-422-6237) SUBSCRIBER SERVICES: Manage Subscriptions  |  Help

 

This email was sent to myhcistech.healthnews360@blogger.com using GovDelivery Communications Cloud on behalf of: National Cancer Institute · BG 9609 MSC 9760 · 9609 Medical Center Drive · Bethesda, MD 20892